Sex differences in adverse drug events for antihypertensive agents
A new Swedish study have analyzed sex differences in spontaneous adverse drug events (ADE) for antihypertensives between 2005-2012. In women, a higher prevalence of ADE reports were seen for following pharmacological groups: ACE inhibitors, combination of ACE inhibitor and thiazide, angiotensine II antagonists, combination of angiotensin II antagonist and thiazide, thiazides, and potassium-sparing agents. Aldosteron antagonists was the only pharmacological group with higher prevalence of ADE reports among men.
Coronary artery disease in post-menopausal women
A newly publiced review provides a current perspective on sex differences in coronary artery disease (CAD) and limitations of assessing CAD in post-menopausal women. Novel tools for assessing CAD in post-menopausal women are highlighted.
Sex distribution in drug trials in cariovascular disease examined
The U.S. Food and Drug Administration (FDA) have investigated women's participation in pivotal cardiovascular disease (CVD) trials for drugs receiving FDA approval between 2005-2015. Representation of women was too low i relation to disease prevalence in studies in heart failure, coronary artery disease, and acute coronary syndrome. Representation of men was too low i studies in pulmonell hypertension. No differences between men and women in drug efficacy and safety were observed.
Janusmed Sex & Gender is a knowledge bank with structured information on sex and gender aspects on drug treatment. The information is aimed towards healthcare personal. It is possible to search on generic names in English and trade names of drug products on the Swedish market. For detailed information on how to search, click on Search help in the blue search field. The purpose of the web site is to improve drug treatment by providing information on whether drug choice or drug dosing need to consider the patient's sex.
Please note that Janusmed Sex & Gender does not include information on teratogenic effects or compatibility with breast feeding. For this information, please consult the databases Janusmed Drugs and Birth Defects and Janusmed Drugs and Breastfeeding, respectively (in Swedish).
The Health and Medical Care Administration at the Stockholm County Council is responsible for the web site. The work is done in collaboration between the Drug Therapeutic Committee in Stockholm County Council, Department of Clinical Pharmacology, Karolinska University Hospital and Centre for Gender Medicine, Karolinska Institutet.